[{"id":"018939bf-e650-44e5-869f-abf3c7f78aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01386502","created_at":"2021-01-18T05:41:19.313Z","updated_at":"2024-07-02T16:37:20.472Z","phase":"Phase 1","brief_title":"CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors","source_id_and_acronym":"NCT01386502","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pidilizumab (CT-011)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/15/2011","start_date":" 06/15/2011","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 10/31/2011","study_completion_date":" 10/31/2011","last_update_posted":"2017-07-02"}]